Company research
AtriCure, Inc.
CIK 1323885Updated Sep 27, 2026
SecurityATRC · NASDAQ · equity
ATRC price & chart
Loading TradingView…
NASDAQ:ATRC on TradingView ↗About the company
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® and cryoXT® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac, thoracic and amputation procedures. For more information, visit AtriCure.com or follow us on X @AtriCure.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 654,179,000Source | 609,328,000Source | 613,932,000Source | 585,448,000Source |
| GoodwillUSD | 234,781,000Source | 234,781,000Source | 234,781,000Source | 234,781,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 48,026,000Source | 56,467,000Source | 63,986,000Source | 39,339,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 167,428,000Source | 122,721,000Source | 84,310,000Source | 58,099,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 66,653,000Source | 60,339,000Source | 52,501,000Source | 42,693,000Source |
| Inventory, NetUSD | 78,492,000Source | 75,335,000Source | 67,897,000Source | 45,931,000Source |
| Assets, CurrentUSD | 322,517,000Source | 267,826,000Source | 266,246,000Source | 215,214,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 9,944,000Source | 9,431,000Source | 8,563,000Source | 5,477,000Source |
| Operating Lease, Right-of-Use AssetUSD | 6,868,000Source | 5,727,000Source | 4,324,000Source | 3,787,000Source |
| Other Assets, NoncurrentUSD | 2,864,000Source | 2,868,000Source | 2,160,000Source | 1,985,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 162,244,000Source | 148,359,000Source | 147,764,000Source | 128,694,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 50,000Source | 49,000Source | 48,000Source | 47,000Source |
| Retained Earnings (Accumulated Deficit)USD | -413,203,000Source | -401,755,000Source | -357,057,000Source | -326,619,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 566,000Source | -1,035,000Source | -993,000Source | -4,096,000Source |
| Stockholders' Equity Attributable to ParentUSD | 491,935,000Source | 460,969,000Source | 466,168,000Source | 456,754,000Source |
| Additional Paid in Capital, Common StockUSD | 904,522,000Source | 863,710,000Source | 824,170,000Source | 787,422,000Source |
| Liabilities and EquityUSD | 654,179,000Source | 609,328,000Source | 613,932,000Source | 585,448,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 81,520,000Source | 73,424,000Source | 74,569,000Source | 58,392,000Source |
| Operating Lease, Liability, CurrentUSD | 1,734,000Source | 1,619,000Source | 1,447,000Source | 1,147,000Source |
| Accounts Payable, CurrentUSD | 25,310,000Source | 25,032,000Source | 27,354,000Source | 19,898,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,541,000Source | 4,579,000Source | 3,307,000Source | 3,095,000Source |
| Other Liabilities, NoncurrentUSD | 7,343,000Source | 1,210,000Source | 1,234,000Source | 1,226,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 53,089,000Source | 45,587,000Source | 44,682,000Source | 33,022,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 61,865,000Source | 61,865,000Source | 60,593,000Source | 56,834,000Source |
| Short-term InvestmentsUSD | — | 0Source | 52,975,000Source | 63,014,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 44,685,000Source | 40,405,000Source | 35,728,000Source | 28,771,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 5,610,000Source | 8,301,000Source | 9,872,000Source | 8,989,000Source |
| Increase (Decrease) in InventoriesUSD | 2,256,000Source | 7,740,000Source | 21,830,000Source | 7,305,000Source |
| Increase (Decrease) in Accounts PayableUSD | -960,000Source | -1,531,000Source | 6,177,000Source | 2,677,000Source |
| Deferred Income Tax Expense (Benefit)USD | -62,000Source | 6,000Source | -15,000Source | 8,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 57,334,000Source | 12,204,000Source | 4,484,000Source | -22,141,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -14,550,000Source | 30,234,000Source | 21,817,000Source | 44,006,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 9,050,000Source | 11,459,000Source | 11,998,000Source | 16,881,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 11,163,000Source | 6,951,000Source | 6,557,000Source | 12,201,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 1,176,000Source | -3,603,000Source | -32,000Source | -7,059,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | 6,250,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 44,707,000Source | 38,411,000Source | 26,211,000Source | 14,445,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 167,428,000Source | 122,721,000Source | 84,310,000Source | 58,099,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 5,255,000Source | 5,951,000Source | 6,376,000Source | 4,270,000Source |
| Income Taxes Paid, NetUSD | 1,290,000Source | 619,000Source | 395,000Source | 192,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 747,000Source | -424,000Source | -58,000Source | -361,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 44,685,000Source | 40,405,000Source | 35,728,000Source | 28,771,000Source |
| Amortization of Debt Issuance CostsUSD | 478,000Source | 478,000Source | 486,000Source | 507,000Source |
| Amortization of Intangible AssetsUSD | 8,441,000Source | 7,519,000Source | 5,353,000Source | 3,653,000Source |
| DepreciationUSD | 12,090,000Source | 11,214,000Source | 9,460,000Source | 8,057,000Source |
| Gain (Loss) on InvestmentsUSD | 0Source | 0Source | 0Source | 0Source |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | -1,362,000Source | — | — |
| GoodwillUSD | 234,781,000Source | 234,781,000Source | 234,781,000Source | 234,781,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | 1,285,000Source | 1,024,000Source | 591,000Source | 268,000Source |
| InterestExpenseNonoperatingUSD | 5,878,000Source | 6,407,000Source | — | — |
| Investment Income, InterestUSD | 4,479,000Source | 4,434,000Source | 3,792,000Source | 1,994,000Source |
| Net Income (Loss) Attributable to ParentUSD | -11,448,000Source | -44,698,000Source | -30,438,000Source | -46,466,000Source |
| Operating ExpensesUSD | 410,226,000Source | 387,537,000Source | 327,053,000Source | 288,609,000Source |
| Other Nonoperating Income (Expense)USD | 683,000Source | -326,000Source | -31,000Source | -537,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 0Source |
| Proceeds from Issuance of Long-term DebtUSD | 0Source | 61,210,000Source | 0Source | 0Source |
| Proceeds from Stock Options ExercisedUSD | 1,367,000Source | 1,022,000Source | 2,316,000Source | 1,816,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | -800,000Source | -3,698,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 534,528,000Source | 465,307,000Source | 399,245,000Source | 330,379,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 311,017,000Source | 291,359,000Source | 253,138,000Source | 231,272,000Source |
| Operating Income (Loss)USD | -9,447,000Source | -40,013,000Source | -26,683,000Source | -42,669,000Source |
| Other Nonoperating Income (Expense)USD | 683,000Source | -326,000Source | -31,000Source | -537,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -10,163,000Source | -43,674,000Source | -29,847,000Source | -46,198,000Source |
| Income Tax Expense (Benefit)USD | 1,285,000Source | 1,024,000Source | 591,000Source | 268,000Source |
| Net Income (Loss) Attributable to ParentUSD | -11,448,000Source | -44,698,000Source | -30,438,000Source | -46,466,000Source |
| Earnings Per Share, BasicUSD per share | -0.24Source | -0.95Source | -0.66Source | -1.02Source |
| Earnings Per Share, DilutedUSD per share | -0.24Source | -0.95Source | -0.66Source | -1.02Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 47,750,000Source | 46,965,000Source | 46,309,000Source | 45,740,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 47,750,000Source | 46,965,000Source | 46,309,000Source | 45,740,000Source |
| Interest Expense (non-operating)USD | 5,878,000Source | 6,407,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 8,441,000Source | 7,519,000Source | 5,353,000Source | 3,653,000Source |
| Current Income Tax Expense (Benefit)USD | 1,347,000Source | 1,018,000Source | 606,000Source | 260,000Source |
| Gain (Loss) on InvestmentsUSD | 0Source | 0Source | 0Source | 0Source |
| Gross ProfitUSD | 400,779,000Source | 347,524,000Source | 300,370,000Source | 245,940,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -8,811,000Source | -36,983,000Source | -17,822,000Source | -38,008,000Source |
| Interest ExpenseUSD | — | — | 6,925,000Source | 4,986,000Source |
| Investment Income, InterestUSD | 4,479,000Source | 4,434,000Source | 3,792,000Source | 1,994,000Source |
| Operating ExpensesUSD | 410,226,000Source | 387,537,000Source | 327,053,000Source | 288,609,000Source |
| Research and Development ExpenseUSD | 99,209,000Source | 96,178,000Source | 73,915,000Source | 57,337,000Source |
Filing attachments
d43112dex991.htm · 8-K · 2026-01-12
EX-99.1 3 d43112dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 For immediate release January 12, 2026 AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026 MASON, Ohio, January 12, 2026 - AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fo…
Read attachment ↗